Multiple Myeloma Trial Stopped Early Due to Significant Efficacy Advantage of Bortezomib

Publication
Article
OncologyONCOLOGY Vol 21 No 11
Volume 21
Issue 11

Millennium Pharmaceuticals, Inc, announced that the interim analysis results of the large, international phase III VISTA trial in patients with newly diagnosed multiple myeloma showed that VMP therapy (bortezomib [Velcade], melphalan [Alkeran], and prednisone) demonstrated a highly statistically significant improvement in all efficacy measures, including time-to-disease progression, complete remission rate, progression-free survival, and overall survival, compared to MP (melphalan and prednisone) alone.

Millennium Pharmaceuticals, Inc, announced that the interim analysis results of the large, international phase III VISTA trial in patients with newly diagnosed multiple myeloma showed that VMP therapy (bortezomib [Velcade], melphalan [Alkeran], and prednisone) demonstrated a highly statistically significant improvement in all efficacy measures, including time-to-disease progression, complete remission rate, progression-free survival, and overall survival, compared to MP (melphalan and prednisone) alone. Based on the recommendation of an independent data monitoring committee after a planned interim analysis, the control arm of the trial was stopped early to allow patients still being treated with MP to have bortezomib added to their therapy.

"These results position Velcade-based therapy as a new standard of care for newly diagnosed multiple myeloma patients," said Paul Richardson, MD, associate professor of medicine, Harvard Medical School; clinical director, Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Boston; and a lead investigator of the VISTA trial. "The combination of Velcade with melphalan and prednisone surpassed all efficacy endpoints, including time-to-disease progression, complete remission rate, progression-free survival, and overall survival, and did so much earlier than expected. We are excited at the possibility this new therapy could be available to our patients sooner."

Recent Videos
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Related Content